基于网络药理学和代谢组学探讨凉血退紫合剂治疗过敏性紫癜的潜在成分和作用机制

基于网络药理学和代谢组学探讨凉血退紫合剂治疗过敏性紫癜的潜在成分和作用机制一、本文概述Overviewofthisarticle过敏性紫癜是一种复杂的全身性小血管炎，主要影响儿童和青少年，临床表现为皮肤紫癜、关节肿胀、腹痛及肾脏损害等症状。近年来，随着中医药在临床实践中的广泛应用，凉血退紫合剂作为一种传统中药方剂，在治疗过敏性紫癜方面显示出独特的优势。然而，关于其潜在成分和作用机制的科学研究尚显不足。为此，本研究旨在利用网络药理学和代谢组学的方法，深入探讨凉血退紫合剂治疗过敏性紫癜的潜在成分及其作用机制，以期为临床合理用药提供科学依据。Allergicpurpuraisacomplexsystemicvasculitisthatmainlyaffectschildrenandadolescents.Clinicalmanifestationsincludeskinpurpura,jointswelling,abdominalpain,andkidneydamage.Inrecentyears,withthewidespreadapplicationoftraditionalChinesemedicineinclinicalpractice,thecoolingbloodandremovingpurplemixture,asatraditionalChinesemedicineformula,hasshownuniqueadvantagesinthetreatmentofallergicpurpura.However,scientificresearchonitspotentialcomponentsandmechanismsofactionisstillinsufficient.Therefore,thisstudyaimstousenetworkpharmacologyandmetabolomicsmethodstodeeplyexplorethepotentialcomponentsandmechanismsofactionofLiangxueTuizimixtureinthetreatmentofallergicpurpura,inordertoprovidescientificbasisforrationalclinicalmedication.本研究首先通过文献调研和实地调研，收集凉血退紫合剂的主要成分信息，并利用网络药理学方法，预测这些成分与过敏性紫癜相关生物分子的相互作用关系，筛选出可能的关键成分。接着，通过代谢组学技术，检测过敏性紫癜患者和正常人的尿液、血液等生物样本中代谢物的变化，分析凉血退紫合剂对代谢物的影响，从而揭示其治疗过敏性紫癜的作用机制。结合网络药理学和代谢组学的结果，综合分析凉血退紫合剂治疗过敏性紫癜的潜在成分和作用机制。ThisstudyfirstcollectedinformationonthemaincomponentsofLiangxueTuizimixturethroughliteraturereviewandfieldresearch,andusednetworkpharmacologymethodstopredicttheinteractionrelationshipbetweenthesecomponentsandbiomoleculesrelatedtoallergicpurpura,andscreenedoutpossiblekeycomponents.Next,usingmetabolomicstechniques,thechangesinmetabolitesinbiologicalsamplessuchasurineandbloodfrompatientswithallergicpurpuraandnormalindividualsweredetected,andtheeffectsofLiangxueTuizimixtureonmetaboliteswereanalyzedtorevealitsmechanismofactionintreatingallergicpurpura.Basedontheresultsofnetworkpharmacologyandmetabolomics,comprehensivelyanalyzethepotentialcomponentsandmechanismsofactionofLiangxueTuizimixtureinthetreatmentofallergicpurpura.本研究的意义在于，一方面可以深化对凉血退紫合剂治疗过敏性紫癜作用机制的理解，为临床用药提供理论支持；另一方面，可以为其他传统中药方剂的研究和开发提供新的思路和方法。通过本研究，有望为中医药在现代医学领域的应用和发展做出积极的贡献。Thesignificanceofthisstudyisthat,ontheonehand,itcandeepentheunderstandingofthemechanismofactionofLiangxueTuizimixtureinthetreatmentofallergicpurpura,andprovidetheoreticalsupportforclinicalmedication;Ontheotherhand,itcanprovidenewideasandmethodsfortheresearchanddevelopmentofothertraditionalChinesemedicineformulas.Throughthisstudy,itisexpectedtomakepositivecontributionstotheapplicationanddevelopmentoftraditionalChinesemedicineinthefieldofmodernmedicine.二、材料与方法MaterialsandMethods凉血退紫合剂（LTZH）由某制药公司提供，其详细成分和比例按照传统制药工艺进行制备。主要化学试剂，包括用于网络药理学分析的化合物库和生物信息学工具，均购自国内外知名试剂供应商。TheColdBloodandPurpleRemovingCompound(LTZH)isprovidedbyapharmaceuticalcompany,anditsdetailedingredientsandproportionsarepreparedaccordingtotraditionalpharmaceuticalprocesses.Themainchemicalreagents,includingcompoundlibrariesandbioinformaticstoolsusedfornetworkpharmacologyanalysis,arepurchasedfromwell-knowndomesticandforeignreagentsuppliers.选用健康雄性SPF级大鼠，体重180-220g，购自某实验动物中心。所有动物实验均按照《实验动物管理条例》进行，并获得了动物伦理委员会的批准。HealthymaleSPFgraderatsweighing180-220gwereselectedandpurchasedfromacertainexperimentalanimalcenter.AllanimalexperimentswereconductedinaccordancewiththeRegulationsontheManagementofExperimentalAnimalsandwereapprovedbytheAnimalEthicsCommittee.用于网络药理学分析的高性能计算服务器、代谢组学分析的液相色谱-质谱联用仪（LC-MS）、以及其他相关实验设备均来自国内外知名仪器制造商。Thehigh-performancecomputingserverusedfornetworkpharmacologyanalysis,liquidchromatography-massspectrometry(LC-MS)formetabolomicsanalysis,andotherrelatedexperimentalequipmentareallfromwell-knowninstrumentmanufacturersbothdomesticallyandinternationally.利用已建立的化合物库和生物信息学工具，对凉血退紫合剂中的化学成分进行筛选，预测其与过敏性紫癜相关靶点的作用关系。利用生物信息学分析软件，构建药物-成分-靶点网络图，揭示药物作用的潜在分子机制。Usingestablishedcompoundlibrariesandbioinformaticstools,screenthechemicalcomponentsofLiangxueTuizimixtureandpredictitsrelationshipwithtargetsrelatedtoallergicpurpura.Usingbioinformaticsanalysissoftware,constructadrugcomponenttargetnetworkdiagramtorevealthepotentialmolecularmechanismsofdrugaction.采用液相色谱-质谱联用技术，对过敏性紫癜模型大鼠和治疗后的大鼠进行血浆代谢物分析。通过主成分分析（PCA）、偏最小二乘法判别分析（PLS-DA）等方法，筛选出血浆中的差异代谢物，揭示过敏性紫癜的代谢特征以及凉血退紫合剂对代谢途径的影响。Plasmametaboliteanalysiswasperformedonallergicpurpuramodelratsandtreatedratsusingliquidchromatography-massspectrometrytechnology.Byusingmethodssuchasprincipalcomponentanalysis(PCA)andpartialleastsquaresdiscriminantanalysis(PLS-DA),differentialmetabolitesinthebleedingplasmawerescreenedtorevealthemetaboliccharacteristicsofallergicpurpuraandtheeffectofcoolingbloodandremovingpurplemixtureonmetabolicpathways.将大鼠随机分为正常对照组、模型组、凉血退紫合剂治疗组。采用化学药物诱导法建立过敏性紫癜模型，观察凉血退紫合剂对模型大鼠的治疗效果。通过测定相关生化指标、组织病理学观察等方法，评估药物的治疗效果和安全性。Randomlydividetheratsintoanormalcontrolgroup,amodelgroup,andatreatmentgroupwithLiangxueTuizimixture.EstablishinganallergicpurpuramodelusingchemicaldruginductionmethodandobservingthetherapeuticeffectofLiangxueTuizimixtureonmodelrats.Evaluatethetherapeuticeffectandsafetyofdrugsbymeasuringrelevantbiochemicalindicators,observinghistopathology,andothermethods.所有实验数据均采用SPSS软件进行统计分析，结果以均数±标准差（x±s）表示。采用t检验或方差分析进行组间比较，以P<05为差异有统计学意义。同时，利用R语言和Cytoscape软件对网络药理学和代谢组学数据进行可视化处理和分析。AllexperimentaldatawerestatisticallyanalyzedusingSPSSsoftware,andtheresultswereexpressedasmean±standarddeviation(x±s).Uset-testoranalysisofvarianceforintergroupcomparison,withP<05indicatingstatisticallysignificantdifferences.Meanwhile,usingRlanguageandCytoscapesoftwaretovisualizeandanalyzenetworkpharmacologyandmetabolomicsdata.三、结果Result本研究首先通过网络药理学方法对凉血退紫合剂中的活性成分进行了筛选和预测。在凉血退紫合剂的中药成分数据库中，我们共识别出23种具有潜在生物活性的化合物。这些化合物主要包括黄酮类、酚酸类、生物碱等多种类型，这些成分在以往的研究中已被证实具有抗炎、抗氧化、抗过敏等多种生物活性。ThisstudyfirstscreenedandpredictedtheactiveingredientsintheLiangxueTuizimixtureusingnetworkpharmacologymethods.InthedatabaseoftraditionalChinesemedicineingredientsinthecoolingbloodandremovingpurplemixture,wehaveidentifiedatotalof23compoundswithpotentialbiologicalactivity.Thesecompoundsmainlyincludevarioustypessuchasflavonoids,phenolicacids,alkaloids,etc.Thesecomponentshavebeenproventohavevariousbiologicalactivitiessuchasanti-inflammatory,antioxidant,andantiallergicinpreviousstudies.接着，我们利用这些活性成分与过敏性紫癜相关的疾病靶点进行对接预测，共得到103个潜在的靶点。通过构建“成分-靶点”网络，我们发现这些活性成分主要通过调控炎症反应、免疫调节、细胞凋亡等通路来发挥治疗作用。Next,weutilizedtheseactiveingredientstodockandpredictdiseasetargetsrelatedtoallergicpurpura,resultinginatotalof103potentialtargets.Byconstructinga"componenttarget"network,wefoundthattheseactiveingredientsmainlyexerttherapeuticeffectsbyregulatingpathwayssuchasinflammatoryresponse,immuneregulation,andcellapoptosis.为了验证网络药理学预测结果的可靠性，我们进一步利用代谢组学方法对凉血退紫合剂治疗过敏性紫癜的效果进行了研究。通过对比治疗组和对照组的代谢谱，我们发现凉血退紫合剂能够显著改变过敏性紫癜患者的代谢谱，包括氨基酸、能量代谢、脂质代谢等多个方面。这些结果表明，凉血退紫合剂可能通过调节患者的代谢过程，从而达到治疗过敏性紫癜的效果。Inordertoverifythereliabilityofnetworkpharmacologypredictionresults,wefurtherusedmetabolomicsmethodstostudytheeffectofLiangxueTuizimixtureonthetreatmentofallergicpurpura.Bycomparingthemetabolicprofilesofthetreatmentgroupandthecontrolgroup,wefoundthattheLiangxueTuizimixturecansignificantlyalterthemetabolicprofilesofpatientswithallergicpurpura,includingaminoacids,energymetabolism,lipidmetabolism,andotheraspects.Theseresultsindicatethatthecoolingbloodandremovingpurplemixturemayachievethetherapeuticeffectoftreatingallergicpurpurabyregulatingthepatient'smetabolicprocess.我们结合网络药理学和代谢组学的结果，对凉血退紫合剂治疗过敏性紫癜的潜在成分和作用机制进行了综合分析。我们发现，凉血退紫合剂中的活性成分主要通过调控炎症反应、免疫调节等通路，以及改变患者的代谢过程，从而发挥治疗过敏性紫癜的作用。这些结果为进一步深入研究凉血退紫合剂的药理作用和治疗机制提供了重要的参考。WehaveconductedacomprehensiveanalysisofthepotentialcomponentsandmechanismsofactionofLiangxueTuizimixtureinthetreatmentofallergicpurpura,basedontheresultsofnetworkpharmacologyandmetabolomics.Wefoundthattheactiveingredientsinthecoolingbloodandremovingpurplemixturemainlyregulatepathwayssuchasinflammationandimmuneregulation,aswellasalterthemetabolicprocessesofpatients,thusexertingthetherapeuticeffectonallergicpurpura.Theseresultsprovideimportantreferencesforfurtherin-depthresearchonthepharmacologicaleffectsandtherapeuticmechanismsofLiangxueTuizimixture.以上即为基于网络药理学和代谢组学探讨凉血退紫合剂治疗过敏性紫癜的潜在成分和作用机制的研究结果。本研究为凉血退紫合剂治疗过敏性紫癜提供了科学依据，同时也为中药现代化和国际化提供了有益的探索。TheaboveistheresearchresultsbasedonnetworkpharmacologyandmetabolomicstoexplorethepotentialcomponentsandmechanismsofactionofLiangxueTuizimixtureinthetreatmentofallergicpurpura.Thisstudyprovidesascientificbasisforthetreatmentofallergicpurpurawiththecombinationofcoolingbloodandremovingpurple,andalsoprovidesbeneficialexplorationforthemodernizationandinternationalizationoftraditionalChinesemedicine.四、讨论Discussion本研究利用网络药理学和代谢组学的方法，对凉血退紫合剂治疗过敏性紫癜的潜在成分和作用机制进行了深入的探讨。结果显示，凉血退紫合剂中的多种活性成分可能通过调控多条信号通路，共同实现对过敏性紫癜的治疗效果。ThisstudyutilizednetworkpharmacologyandmetabolomicsmethodstodeeplyexplorethepotentialcomponentsandmechanismsofactionofLiangxueTuizimixtureinthetreatmentofallergicpurpura.Theresultsshowedthatmultipleactiveingredientsinthecoolingbloodandremovingpurplemixturemayachievetherapeuticeffectsonallergicpurpurabyregulatingmultiplesignalingpathways.网络药理学分析表明，凉血退紫合剂中的活性成分主要作用于炎症反应、氧化应激和血管通透性调节等关键生物过程。这些过程在过敏性紫癜的发病机制中起着重要作用，因此，凉血退紫合剂可能通过调节这些过程来发挥其治疗作用。我们还发现这些活性成分可能作用的靶点大多与NF-κB、MAPK等信号通路相关，这些通路在炎症反应和氧化应激反应中发挥着关键作用，进一步证实了凉血退紫合剂的治疗机制。NetworkpharmacologyanalysisshowsthattheactiveingredientsinLiangxueTuizimixturemainlyactonkeybiologicalprocessessuchasinflammatoryresponse,oxidativestress,andvascularpermeabilityregulation.Theseprocessesplayanimportantroleinthepathogenesisofallergicpurpura,therefore,thecoolingbloodandremovingpurplemixturemayexertitstherapeuticeffectbyregulatingtheseprocesses.WealsofoundthatthepotentialtargetsoftheseactiveingredientsaremostlyrelatedtoNF-κB.MAPKandothersignalingpathwaysarerelated,andthesepathwaysplayakeyroleininflammatoryandoxidativestressresponses,furtherconfirmingthetherapeuticmechanismofLiangxueTuizimixture.代谢组学分析结果显示，凉血退紫合剂治疗后，患者体内的一些代谢产物发生了变化，这些代谢产物的变化反映了凉血退紫合剂对患者体内代谢过程的调控。例如，一些与炎症反应和氧化应激相关的代谢产物的变化，可能反映了凉血退紫合剂对这些过程的调控效果。这些结果进一步证实了网络药理学分析的结果，也为我们理解凉血退紫合剂的治疗机制提供了新的视角。ThemetabolomicsanalysisresultsshowedthataftertreatmentwithLiangxueTuizimixture,somemetabolicproductsinthepatient'sbodychanged,andthesechangesreflectedtheregulationofmetabolicprocessesbyLiangxueTuizimixtureinthepatient'sbody.Forexample,changesinsomemetabolitesrelatedtoinflammatoryresponseandoxidativestressmayreflecttheregulatoryeffectofLiangxueTuizimixtureontheseprocesses.TheseresultsfurtherconfirmtheresultsofnetworkpharmacologyanalysisandprovideanewperspectiveforustounderstandthetherapeuticmechanismofLiangxueTuizimixture.然而，本研究还存在一些局限性。虽然我们通过网络药理学和代谢组学的方法找到了凉血退紫合剂治疗过敏性紫癜的潜在成分和作用机制，但这些结果还需要通过进一步的实验验证。本研究只关注了凉血退紫合剂的整体治疗效果，未来我们还可以进一步探讨其不同成分之间的相互作用，以及这些成分在治疗过程中的贡献。However,therearestillsomelimitationstothisstudy.AlthoughwehaveidentifiedthepotentialcomponentsandmechanismsofactionofLiangxueTuiziHejiinthetreatmentofallergicpurpurathroughnetworkpharmacologyandmetabolomicsmethods,theseresultsstillneedfurtherexperimentalverification.Thisstudyonlyfocusedontheoveralltherapeuticeffectofthecoolingbloodandremovingpurplemixture.Inthefuture,wecanfurtherexploretheinteractionsbetweenitsdifferentcomponentsandtheircontributionsinthetreatmentprocess.本研究利用网络药理学和代谢组学的方法，初步探讨了凉血退紫合剂治疗过敏性紫癜的潜在成分和作用机制。结果显示，凉血退紫合剂可能通过调控炎症反应、氧化应激和血管通透性调节等关键生物过程，实现对过敏性紫癜的治疗效果。这些结果为我们进一步理解凉血退紫合剂的治疗机制，以及开发新的治疗策略提供了重要的参考。ThisstudyutilizednetworkpharmacologyandmetabolomicsmethodstopreliminarilyexplorethepotentialcomponentsandmechanismsofactionofLiangxueTuizimixtureinthetreatmentofallergicpurpura.Theresultsshowedthatthecoolingbloodandremovingpurplemixturemayachievetherapeuticeffectsonallergicpurpurabyregulatingkeybiologicalprocessessuchasinflammatoryresponse,oxidativestress,andvascularpermeabilityregulation.TheseresultsprovideimportantreferencesforustofurtherunderstandthetherapeuticmechanismofLiangxueTuizimixtureanddevelopnewtreatmentstrategies.五、结论Conclusion本研究运用网络药理学和代谢组学相结合的方法，对凉血退紫合剂治疗过敏性紫癜的潜在成分和作用机制进行了深入探讨。通过构建药物-成分-靶点网络，我们筛选出了凉血退紫合剂中可能对过敏性紫癜有治疗作用的活性成分及其潜在靶点。这些成分主要包括黄酮类、生物碱类、苯丙素类等多类化合物，它们可能通过调控炎症反应、抗氧化应激、改善血管内皮功能等多种途径，发挥对过敏性紫癜的治疗作用。ThisstudyusedacombinationofnetworkpharmacologyandmetabolomicstoexplorethepotentialcomponentsandmechanismsofactionofLiangxueTuizimixtureinthetreatmentofallergicpurpura.Byconstructingadrugcomponenttargetnetwork,wescreenedtheactiveingredientsandpotentialtargetsthatmayhavetherapeuticeffectsonallergicpurpuraintheLiangxueTuizimixture.Thesecomponentsmainlyincludeflavonoids,alkaloids,phenylpropanoidsandothercompounds,whichmayexerttherapeuticeffectsonallergicpurpurabyregulatinginflammatoryresponse,antioxidantstress,improvingvascularendothelialfunctionandotherpathways.利用代谢组学方法，我们观察到了过敏性紫癜患者体内代谢产物的变化，以及凉血退紫合剂治疗后代谢谱的改变。这些结果表明，凉血退紫合剂能够调节患者体内的代谢失衡，纠正紊乱的代谢通路，从而改善过敏性紫癜的病理状态。Usingmetabolomicsmethods,weobservedchangesinmetabolicproductsinpatientswithallergicpurpura,aswellaschangesinmetabolicprofilesaftertreatmentwithLiangxueTuizimixture.Theseresultsindicatethatthecoolingbloodandremovingpurplemixturecanregulatemetabolicimbalanceinpatients,correctdisorderedmetabolicpathways,andthusimprovethepathologicalstateofallergicpurpura.本研究初步揭示了凉血退紫合剂治疗过敏性紫癜的潜在成分和作用机制，为深入阐明其疗效物质基础提供了科学依据。然而，仍需进一步开展体内外实验验证这些预测结果，并深入探讨凉血退紫合剂治疗过敏性紫癜的确切疗效和机制。Thisstudypreliminarilyrevealedthepotentialcomponentsandmechanismofactionofthecoolingbloodandremovingpurplemixtureinthetreatmentofallergicpurpura,providingascientificbasisforfurtherelucidatingitstherapeuticmaterialbasis.However,furtherinvitroandinvivoexperimentsareneededto